Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2006) 11 P532

ECE2006 Poster Presentations Endocrine tumours and neoplasia (116 abstracts)

The value of fluorine-18 fluorodeoxyglucose PET during follow-up of patients with medullary thyroid carcinoma

GA Lupoli 1 , S Colarusso 1 , A Panico 1 , F Fonderico 1 , F Nappi 1 , F Marciello 1 , A Gonnella 1 , MR Poggiano 1 , E Nicolai 2 , M Salvatore 2 & G Lupoli 1


1Department of Molecular and Clinical Endocrinology and Oncology - University Federico II, Naples, Italy; 2Department of Functional and Biomorphological Sciences, University Federico II, Naples, Italy.


Introduction: Fluorine-18 fluorodeoxyglucose positron emission tomography (18F-FDG PET) is an innovative method for the detection of primary tumours or metastases of thyroid cancer; however, recurrence or metastases of medullary thyroid carcinoma (MTC) are still difficult to detect.

Aim: The objective of this study was to evaluate the clinical use of 18F-FDG PET in patients with MTC.

Patients and methods: We enrolled 11 patients with MTC, presenting elevated serum calcitonin levels during post-surgical follow-up. They underwent 18F-FDG PET and conventional imaging techniques: ultrasonography (US), magnetic resonance (MR), computerized tomography (CT), 111In-DTPA-Phe-octreotide (Octreoscan), 131I-MIBG scintigraphy.

Results and discussion: 18F-FDG PET was positive in 7 cases: 2 of them were false positive results - 1 due to pneumonia and 1 to post-surgical fibrosis in the thyroid bed. In the remaining 5 patients, 18F-FDG PET detected tumour foci, confirmed also by CT, MR, Octreoscan and 131I-MIBG scintigraphy in 4, and by histology in 1 of them. 4 patients showed completely negative 18F-FDG PET scans: 2 results were true negative, as confirmed also by other techniques, whereas 2 were false negative (in the first one a secondary lesion localized in the pulmonary region was detected only by CT, while in the second loco-regional lymph node metastases were correctly identified by Octreoscan).

18F-FDG PET was able to identify the metastatic foci as efficiently as the conventional imaging techniques and to localize a previously unknown tumour relapse in one patient; nevertheless, 2 false positive and 2 false negative results were recorded.

Conclusion: 18F-FDG PET appears to be a valuable and useful tool when used in association with other morphological and functional diagnostic imaging techniques during the follow-up of MTC patients with increased serum tumour markers.

Volume 11

8th European Congress of Endocrinology incorporating the British Endocrine Societies

European Society of Endocrinology 
British Endocrine Societies 

Browse other volumes

Article tools

My recent searches

No recent searches.